CYBN
Price
$9.13
Change
+$0.20 (+2.24%)
Updated
Jan 17 closing price
Capitalization
183.31M
MNMD
Price
$7.16
Change
+$0.65 (+9.98%)
Updated
Jan 17 closing price
Capitalization
524.69M
79 days until earnings call
Ad is loading...

CYBN vs MNMD

Header iconCYBN vs MNMD Comparison
Open Charts CYBN vs MNMDBanner chart's image
Cybin
Price$9.13
Change+$0.20 (+2.24%)
Volume$167.62K
Capitalization183.31M
Mind Medicine (MindMed)
Price$7.16
Change+$0.65 (+9.98%)
Volume$2.87M
Capitalization524.69M
CYBN vs MNMD Comparison Chart
Loading...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYBN vs. MNMD commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYBN is a Hold and MNMD is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CYBN: $9.13 vs. MNMD: $7.16)
Brand notoriety: CYBN and MNMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYBN: 42% vs. MNMD: 200%
Market capitalization -- CYBN: $183.31M vs. MNMD: $524.69M
CYBN [@Biotechnology] is valued at $183.31M. MNMD’s [@Biotechnology] market capitalization is $524.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYBN’s FA Score shows that 1 FA rating(s) are green whileMNMD’s FA Score has 1 green FA rating(s).

  • CYBN’s FA Score: 1 green, 4 red.
  • MNMD’s FA Score: 1 green, 4 red.
According to our system of comparison, MNMD is a better buy in the long-term than CYBN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYBN’s TA Score shows that 3 TA indicator(s) are bullish while MNMD’s TA Score has 2 bullish TA indicator(s).

  • CYBN’s TA Score: 3 bullish, 5 bearish.
  • MNMD’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, CYBN is a better buy in the short-term than MNMD.

Price Growth

CYBN (@Biotechnology) experienced а +2.70% price change this week, while MNMD (@Biotechnology) price change was +3.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CYBN is expected to report earnings on Nov 13, 2024.

MNMD is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNMD($525M) has a higher market cap than CYBN($183M). CYBN YTD gains are higher at: 3.515 vs. MNMD (2.802). MNMD has higher annual earnings (EBITDA): -93.47M vs. CYBN (-130.23M). MNMD has more cash in the bank: 295M vs. CYBN (154M). CYBN has less debt than MNMD: CYBN (133K) vs MNMD (24.3M). CYBN (0) and MNMD (0) have equivalent revenues.
CYBNMNMDCYBN / MNMD
Capitalization183M525M35%
EBITDA-130.23M-93.47M139%
Gain YTD3.5152.802125%
P/E RatioN/AN/A-
Revenue00-
Total Cash154M295M52%
Total Debt133K24.3M1%
FUNDAMENTALS RATINGS
MNMD: Fundamental Ratings
MNMD
OUTLOOK RATING
1..100
72
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
PROFIT vs RISK RATING
1..100
84
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
42
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CYBNMNMD
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 11 days ago
90%
Momentum
ODDS (%)
Bullish Trend 11 days ago
66%
Bearish Trend 11 days ago
83%
MACD
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 11 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
63%
Bullish Trend 11 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
87%
Advances
ODDS (%)
Bullish Trend 13 days ago
79%
Bullish Trend 12 days ago
84%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 20 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
85%
Aroon
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
89%
View a ticker or compare two or three
Ad is loading...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGDCX23.260.16
+0.69%
Fidelity Advisor Gold C
AFCWX16.100.10
+0.63%
American Century Focused Intl Gr R
FCPVX21.180.11
+0.52%
Fidelity Small Cap Value Fund
RYWAX52.330.27
+0.52%
Rydex S&P SmallCap 600 Pure Growth H
AGAWX12.310.03
+0.24%
Allspring Global Long/Short Equity R6

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
+2.24%
ATAI - CYBN
40%
Loosely correlated
+5.04%
SNPX - CYBN
30%
Poorly correlated
N/A
MNMD - CYBN
29%
Poorly correlated
+9.91%
HEPA - CYBN
29%
Poorly correlated
+4.22%
CING - CYBN
25%
Poorly correlated
-4.42%
More

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with LABFF. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then LABFF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
+9.91%
LABFF - MNMD
47%
Loosely correlated
N/A
ATAI - MNMD
46%
Loosely correlated
+5.04%
IMRN - MNMD
45%
Loosely correlated
+8.59%
VCYT - MNMD
40%
Loosely correlated
-1.27%
EYPT - MNMD
37%
Loosely correlated
+2.89%
More